As EPP suppressed the STAT3 and MET/AKT pathways, which stimulate tumor growth and confer EGFR TKI resistance, EPP could be applied not only to EGFR TKI-naïve or -sensitive NSCLC, but also to EGFR TKI-resistant NSCLC. Here, AKT1 is linked to non-small cell lung carcinoma.